Health Condition 1: E669- Obesity, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients with Obesity (BMI 25 to 35 kg/m2, WHO Asia Pacific Guidelines) 2)Participants who are well-oriented in time, and space & as a person 3)Provide written informed consent 4)Physical and mental ability to take part in the study 5)No severe health issues and have not been hospitalized in the past six months 6)Agree to examinations as per the study protocol, undergo the lifestyle intervention program & post-program evaluation
Exclusion criteria
Exclusion criteria: 1) Pregnant and lactating women were excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) At least a 10% reduction in weight at one year and BMI drop below 23 or at least 3-point dropTimepoint: 1) Reduction in weight and BMI drop will be measured at baseline and at the end of the 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Improvement in body composition (BC) parameters (fat percent, visceral fat percent, sub-cutaneous fat percent, skeletal muscle mass) 2)Improvement in Mental Health outcomes for Anxiety and Depression (in terms of reduction in scores below 10 for both anxiety and depression) 3)Improvement in sleep quality (in terms of reduction in scores below 5) 4)Improvement in physical activity levels (in terms of increased metabolic equivalent of task (MET) values above 600 MET-minutes/week) 5)Improvement in co-morbidities and complications (Prediabetes,T2D, Dyslipidemia,Hypertension) 6)Improvement in biochemical parameters- serum lipids, HbA1c, fasting and post-prandial blood glucose levels. serum creatinine, eGFR, SGPT, SGOT, urine microalbuminuria, and C-reactive protein Timepoint: 1)Improvement in body composition will be measured at baseline and at the end of the 12 months. 2)Improvement in Mental health and Sleep quality- At baseline and at 6 months 3)Physical activity assessment at baseline and 12 months 4)For biochemical parameters- At baseline, and at the end of 12 months 5)Co-morbidities and complications- At baseline, and at 12 months | — |
Countries
India
Contacts
Freedom From Diabetes Research Foundation